Recro Pharma changed its name to Societal CDMO to reflect the company’s expansion as a result of the acquisition of IriSys.
Recro Pharma announced on March 21, 2022 that it changed its name to Societal CDMO. The name change reflects the expansion and transformation of the company as a result of the acquisition and integration of IriSys, a contract development and manufacturing organization (CDMO) focused on product development and good manufacturing practice (GMP) manufacturing.
Societal CDMO focuses on solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development. The addition of IriSys in August 2021 expanded the company’s physical footprint to include facilities on both US coasts, diversification of its customer base, more service offerings, and enhancement of its industry expertise. The services of the company will now encompass therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, and packaging and logistic services to the global pharmaceutical market.
“When we set out to rebrand Recro, we sought a name and identity that carried with it a purpose, one which exemplified the commitment our employees demonstrate every day to making a positive impact within communities across the country and around the world,” said David Enloe, CEO of Societal CDMO, in the press release. “At the same time, we were also focused on effectively communicating our evolution as a partner to our clients, as well as our people, both today and in the future. We believe the name Societal CDMO, along with our new tagline of ‘Bringing Science to Society,’ captures not only where we find ourselves as a company today, but it reflects our inspiration for future growth as an organization.”
Source: Recro
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.